Clinical Trials Directory

Randomized Controlled Pilot Trial of Pregnenolone in Autism

This is a research study to examine the tolerability and effectiveness of pregnenolone in individuals with autism. Pregnenolone is a naturally occurring steroid hormone in the brain that has been implicated in treating various psychiatric conditions. The investigators hope to learn the effects and safety of using pregnenolone in reducing irritability and sensitivity to sensory differences and improving social communication in individuals with autism. The investigators hope by studying the effects of pregnenolone in more detail, the investigators can design better ways to treat individuals with autism.

Stanford is now accepting new patients for this trial.

Investigator(s):

Intervention(s):

  • drug : Placebo
  • drug : Pregnenolone

Phase: Phase 2

Eligibility

Ages Eligible For Study:

14 Years - 21 Years

Inclusion Criteria

- outpatients between 14 and 21 years of age with a Tanner stage of V; - male and female subjects who were physically healthy; - diagnosis of Autism Spectrum Disorder (ASD) based on DSM-5, expert clinical opinion and confirmed with Autism Diagnostic Interview - Revised (ADI-R) and Autism Diagnostic Observation Schedule (ADOS); - Aberrant Behavior Checklist -Irritability (ABC-I)? 18 and Clinical Global Impression (CGI)-Severity subscale ? 4; - stable concomitant medications for at least 2 weeks; - no planned changes in psychosocial interventions during the trial.

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Robin Libove
650-736-1235
Recruiting

Footer Links: